Report - LifeSciences BC

More documents

Recommendations

Info

Task Force Mandate and MembershipIn November, 2007 the Minister of Healthestablished a Pharmaceutical Task Force andinvited recommendations regarding how theMinistry of Health could achieve progress in thefollowing areas:1. optimization of the decision making processfor the listing of pharmaceuticals anddevices to produce timely, transparentdecisions based upon sound science whileappropriately protecting the public interest;2. procurement and service delivery optionsfor pharmaceuticals and medical devicesthat will achieve and maximize value topatients and value for money objectives;3. identification and strengthening of commonobjectives related to patient care and choiceand the building of positive relationsbetween government decision makers andindustry to achieve those objectives;4. the effectiveness of the Common DrugReview process and proposals forimprovements;5. the effectiveness, transparency and futurerole of the Therapeutics Initiative insupporting the listing process of drugs, or amore viable and cost-effective alternative.The membership of the Task Force includedsenior industry representatives from the patentmedicine, medical device and retail pharmacycommunities, the Dean of the Faculty ofPharmaceutical Sciences at the University ofBritish Columbia, the Chief Executive Officer ofthe BC Medical Association, two seniorrepresentatives of the Ministry of Health, theformer Auditor General of British Columbia(Alternate Chair) and the President of theUniversity Presidents' Council (Task ForceChair). The Project Charter established to guidethe work of the Task Force is reproduced atSchedule 'A' to this Report.The Task Force met on nine occasions fromDecember of 2007 through to late February of2008. Submissions were received from, and inmost cases the Task Force met with, the BCPharmacists Association, the Canadian GenericPharmaceutical Association, the Canadian1Association of Chain Drug Stores, Rx&D ,MEDEC (Canada's Medical Device TechnologyCompanies), the Better PharmaCare Coalition,the Canadian Diabetes Association and the seniorleadership of the research components of theVancouver Coastal Health Research Institute, theChild and Family Research Institute (ProvincialHealth Services Authority), the ProvidenceHealth Care Research Institute and the SeniorAssociate Dean, Research of the Faculty of2Medicine at the University of British Columbia.1The entity which represents Canada's research-based pharmaceutical companies.2The Dean of Medicine, subsequently made himself available to the Task Force to offer further commentary andclarification, particularly with respect to the operations and accountabilities associated with the TherapeuticsInitiative housed within the Faculty of Medicine.THE REPORT OF PHARMACEUTICAL POLICY RECOMMENDATIONS FOR THE MINISTRY OF HEALTH 1APRIL, 2008
In addition to the submissions from thegroups mentioned above, the Task Force metwith representatives of the National CommonDrug Review (video conference) and UBC'sTherapeutics Initiative, with the AssistantDeputy Minister in the Ministry of Healthresponsible for administration of thePharmaceutical Services Division (PSD) and theExecutive Director of the Drug Intelligence unit ofthe PSD.The Task Force also heard from Dr. ChrisCorbett of CSCW Systems Corporation (CSCW)who was made available by the Ministry of Healthto discuss the content of a Ministry-sponsoredreview CSCW conducted in respect of the3Province's PharmaCare program in 2003/4.Managing Pharmacare: The BC Context1. The Role and Objectives of thePharmaceutical Services DivisionThe Task Force met first with the AssistantDeputy Minister and the Executive Director ofthe Drug Intelligence Unit of the PSD to receivea comprehensive overview of the PSD'sapproach to the administration of pharmaceuticalpolicy, the processes applicable to the evidencebasedreview of submissions for the listing ofnew drug therapies in BC, cost pressures facedby the PharmaCare program and on othercomplex factors which influence theenvironment that program administrators andpolicy makers work within. The discussion withsenior representatives of the PSD addressed:the PSD's Mission, Goals and Objectives;baseline information about thepharmaceutical distribution environmentin BC;the nature of BC's drug review processesincluding the respective roles of the PSD,the Drug Benefit Committee, theTherapeutics Initiative and how BCinteracts with related external processessuch as the national Common Drug Review(CDR) and the Patented Medicine PricesReview Board (PMPRB);the demands on the PSD to effectivelymanage the rising costs associated with thePharmaCare program;the impact cost pressures have ondecisions regarding the province'sformulary management system; andstrategies which have been – or likely willbe – deployed to further contain the cost ofpharmaceutical products eligible forreimbursement under British Columbia'sPharmaCare program.3“Findings of the CSCW Review of PharmaCare”, May 2004.THE REPORT OF PHARMACEUTICAL POLICY RECOMMENDATIONS FOR THE MINISTRY OF HEALTH 2APRIL, 2008
Page 1 and 2: REPORT OF THE PHARMACEUTICAL TASK F
Page 3: Table of ContentsTask Force Mandate
Page 7 and 8: pharmaceutical coverage programs ha
Page 9 and 10: these factors may potentially resul
Page 11 and 12: 14formulary”; andBC should benchm
Page 13 and 14: meaningful engagement with stakehol
Page 15 and 16: contributions from Drs. Ken Bassett
Page 17 and 18: Recommendations for an Improved Lis
Page 19 and 20: Generic Drugs - Call for aFundament
Page 21 and 22: The Task Force also considered thea
Page 23 and 24: was understood that the cost of the
Page 25 and 26: The Task Force believes this is an
Page 27 and 28: participation in decision making, t
Page 29 and 30: Recommendation Twelve:Subject to Re
Page 31 and 32: Recommendation Eight: To increase t
Page 33 and 34: THE REPORT OF PHARMACEUTICAL POLICY

Report - LifeSciences BC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?